## min read

Most Effective Treatment for Bipolar Disorder

By

Sonia Garcia

|

November 3, 2026

Summarize with AI

Most Effective Treatment for Bipolar Disorder

Table of Contents

Example H2
Example H3
Example H4
Example H5
Example H6

Last updated: November 2026.

The most effective treatment for bipolar disorder is usually a combination of medication and psychotherapy, matched to the phase of the illness and continued over the long term. That's the answer most people are looking for, and it is supported by the reviews cited here. According to the National Institute of Mental Health (NIMH), bipolar disorder "usually requires lifelong treatment," but an effective plan helps people manage symptoms and improve their quality of life. A 2013 review in The Lancet by Geddes and Miklowitz organizes the evidence the same way: medication for acute episodes and prevention, with psychological treatment added on top. If you or someone you love was just diagnosed, or just went through a relapse, this guide walks through what each part does and why it matters. You can also read how we approach bipolar disorder treatment at Amae.

What "effective" means when you have bipolar disorder

Treatment has two jobs. The first is ending a current episode, whether that's mania, hypomania, depression, or an episode with mixed features (symptoms of both poles at once). The second, and the one that shapes the years ahead, is preventing the next episode.

Those jobs don't always call for the same tools. A medication that calms acute mania may not be the choice for bipolar depression, and the plan that works during a crisis often changes once mood settles. That's why the American Academy of Family Physicians (AAFP) review from 2021 splits treatment into acute mania, mixed features, acute depression, and maintenance. So when people ask about the best treatment for bipolar disorder, the real reply starts with a question back: best for which phase?

First-line treatment for bipolar disorder: medication by phase

Medication is the base of treatment for most people with bipolar disorder. The main classes are:

  • Mood stabilizers, including lithium and certain anticonvulsants. NIMH notes that some anticonvulsants work better than lithium for certain people, such as those with mixed symptoms or rapid cycling.
  • Atypical antipsychotics, used for mania, mixed episodes, and in some cases bipolar depression or maintenance.
  • Antidepressants, typically given alongside a mood stabilizer because of the risk of switching into mania.

The AAFP review describes mood stabilizers, including lithium, anticonvulsants, and antipsychotics, as a first-line treatment that "should be continued indefinitely because of the risk of patient relapse." Drug-by-drug detail, side effects, and pregnancy considerations are covered in our guide to how mood stabilizers work.

Treating a manic or mixed episode

Acute mania usually needs urgent care. The AAFP review says patients with acute mania require hospitalization because of the risk of harm to themselves or others, and that early goals include adequate sleep and reducing psychotic symptoms; high-quality evidence supports mood stabilizers, including lithium, valproic acid, and antipsychotics. For mixed features, the same review says antidepressants on their own are contraindicated.

Treating bipolar depression

Bipolar depression isn't treated the way Major Depressive Disorder is. An antidepressant on its own can tip some people into mania. For bipolar depression, NIMH says health care providers typically prescribe a mood stabilizer and an antidepressant together to reduce the risk of switching into mania. Some atypical antipsychotics are also used in this phase.

Long-term maintenance

This is where many plans fall apart. People feel well, the medication feels unnecessary, and they stop. Bipolar disorder is a relapsing illness: the AAFP review reports relapse in more than 70% of patients within five years, whatever the treatment, which is why it recommends continuing medication indefinitely. Any change to medication belongs in a conversation with the prescriber, never a quiet decision at home.

Lithium has the longest track record for maintenance. NIMH states that "some studies indicate that lithium may reduce the risk of suicide" among people taking it for long-term maintenance, and that people on lithium need regular monitoring of lithium levels and kidney and thyroid function.

When first options do not work

Some people don't respond to the first or second medication plan. Clinicians then adjust doses, combine medications, or look at other treatments. One of these is electroconvulsive therapy (ECT): the AAFP review states that ECT is effective for mania and psychotic depression. We include it here for education, not as a service we provide.

Therapies that work alongside medication

Medication steadies mood. Therapy builds the skills and routines that keep it steady. The main evidence-based options:

  • Psychoeducation teaches you and your family how the illness behaves, which early signs to watch, and what to do when they show up.
  • Cognitive behavioral therapy (CBT) works on the thoughts and habits that feed depressive episodes and on catching early warning signs.
  • Family-focused therapy brings relatives in to improve communication and plan for relapses together.
  • Interpersonal and social rhythm therapy (IPSRT) stabilizes daily rhythms, especially sleep, meals, and social contact, which are closely tied to mood shifts.

Supportive therapy, a steady relationship with a clinician for problem-solving and encouragement, is also widely used alongside these.

The numbers here are encouraging. A 2021 JAMA Psychiatry review by Miklowitz and colleagues pooled 39 randomized trials with 3,863 participants. Structured psychotherapy added to medication was associated with fewer recurrences than medication plus a control treatment, and family or group psychoeducation did better than individual psychoeducation. For a closer look at each approach, see our guide to supportive therapy for bipolar disorder.

Can bipolar disorder be treated without medication?

Short answer: the research supports therapy and routine changes added to medication, not in place of it. Every trial in the 2021 JAMA Psychiatry review compared medication plus psychotherapy with medication plus a control treatment. None tested therapy alone as a replacement.

That doesn't make the non-medication side minor. It's where much of the day-to-day work happens. As part of a full treatment plan, these habits help:

  • Regular sleep and wake times. AAFP lists sleep hygiene among active lifestyle approaches and names circadian disruption, such as shift work, as an environmental trigger.
  • Avoiding alcohol and drugs. Alcohol and drugs such as cocaine can trigger manic symptoms, and AAFP lists substance use among the things to monitor in ongoing care.
  • Tracking early warning signs. A simple mood and sleep log can show a shift days before it becomes an episode.
  • Managing stress. Psychosocial stress is a known trigger of both manic and depressive symptoms, according to AAFP.
  • Keeping a daily rhythm. Consistent meals, activity, and social contact are the backbone of IPSRT.

If you're thinking about reducing or stopping medication, talk it through with your psychiatrist first. NIMH advises against stopping a prescribed medication without your provider's help, even if you feel better; a provider can lower the dose slowly and safely.

Bipolar I vs. bipolar II: does the most effective treatment differ?

Bipolar I Disorder involves at least one manic episode, which can include psychosis. Bipolar II Disorder involves hypomania, a milder elevated state, along with major depressive episodes. In bipolar II, depression is often what people live with most.

The core principles are shared: medication matched to the phase, therapy added on top, and long-term follow-up. The choices shift with which episodes dominate. AAFP notes that antidepressant monotherapy is contraindicated in bipolar I, mania, and mixed episodes, so the medication conversation looks a little different for each type. Some conditions can look similar to bipolar disorder at first glance; our article on BPD vs. bipolar explains one common source of confusion.

What makes treatment work over the long term

The right medication and the right therapy only work if the plan holds together over years. Over the long term, a few practical things make a large difference:

  • Staying in treatment. AAFP lists treatment adherence among the core parts of ongoing management. Side effects, cost, or simply feeling better are all common reasons people stop, and each one is worth raising with the care team.
  • Watching physical health. Some medications affect the body as well as mood. NIMH notes that people taking atypical antipsychotics may need regular monitoring of weight, glucose, and lipid levels, and lithium requires blood tests.
  • One plan, not three. When the psychiatrist, therapist, and primary care doctor share information, side effects get caught and changes don't conflict.
  • Bringing family in. Relatives often notice an early shift before the person does. The evidence for family psychoeducation points the same way.

When weekly appointments are not enough

Outpatient care, with a psychiatrist and therapist seen every week or few weeks, works for many people. But not during a hard stretch. An IOP (Intensive Outpatient Program) adds several hours of structured treatment a few days a week while you live at home. A PHP (Partial Hospitalization Program) is more intensive, with treatment most of the day on most weekdays. Inpatient care is for times when safety can't be maintained at home. Learn how our intensive outpatient program and partial hospitalization program work, or compare them in PHP vs. IOP.

When to seek help now

Some signs mean an episode may be starting and the care team should hear about it soon. NIMH lists symptoms such as a decreased need for sleep, racing thoughts, and an excessive appetite for pleasurable activities. Others point the other way: sleeping too much and a lack of interest in almost all activities.

Thoughts of self-harm or suicide need help the same day. If you or someone you love is in crisis, call or text 988, or see the FAQ below.

How we treat bipolar disorder at Amae Health

Bipolar disorder is one of the conditions we specialize in at Amae Health. We treat adults 18 and older with severe mental illness (SMI) in in-person outpatient clinics, with care led by psychiatrists. Your team works under one roof: psychiatrists, therapists, primary care physicians, dietitians, health coaches, peer mentors, and clinical care coordinators, all on one treatment plan. When more structure is needed, we offer PHP and IOP. Our tagline, Beyond Care. Towards Cure., means aiming for remission and recovery, not stopping at stability.

To start, see bipolar disorder treatment at Amae or call 1-888-860-2825. When you call, it helps to have a list of your current medications and past treatments ready.

Key takeaways

  • The most effective treatment for bipolar disorder is usually medication plus psychotherapy, continued long term.
  • Treatment depends on the phase: acute mania, bipolar depression, and maintenance each call for different choices.
  • Antidepressants are typically given alongside a mood stabilizer, not on their own.
  • Therapy and daily routines work best added to medication, not as a replacement.
  • Staying in treatment, monitoring physical health, and stepping up the level of care when needed keep a plan working.

Frequently Asked Questions

What is the most effective treatment for bipolar disorder?

For most people, it's a combination of medication and psychotherapy, adjusted to the phase of illness and continued over the long term. NIMH notes that bipolar disorder usually requires lifelong treatment. Therapy added to medication is linked to fewer recurrences.

What is the first-line treatment for bipolar disorder?

Mood stabilizers, such as lithium and certain anticonvulsants, and some atypical antipsychotics. The choice depends on whether the person is in a manic, mixed, or depressive episode, or in maintenance. A psychiatrist weighs the phase, history, and side effects.

What is the most effective treatment for bipolar 2?

The same principles apply: medication, therapy, and long-term follow-up. Depression is often the main focus in bipolar II. Antidepressants are typically prescribed together with a mood stabilizer to reduce the risk of switching into mania.

Is it possible to recover from bipolar disorder?

Bipolar disorder is a long-term condition, but many people reach long periods of stability with ongoing treatment. Recovery here means fewer and milder episodes and a life that works on your terms. Staying in treatment is what protects that.

What is a good daily routine for someone with bipolar disorder?

Regular sleep and wake times, consistent meals, daily activity, and a simple mood log. This idea is at the center of interpersonal and social rhythm therapy. A routine supports treatment; it doesn't replace it.

What should I do if someone with bipolar disorder is in crisis?

Call or text 988 to reach the 988 Suicide and Crisis Lifeline, available 24/7. If someone is in immediate danger, call 911. Stay with the person if it's safe to do so.

Reccomended for you

# min read

How Long Do TMS Results Last? Maintenance and Relapse

By

Sonia Garcia

|

October 10, 2026

Finishing a course of TMS and feeling like yourself again brings a new worry: will it hold? How long do TMS results last, and what happens if the depression comes back? The research is more encouraging than many people expect. Among people who respond to a course, roughly half to nearly two-thirds are still responding a year later, and when symptoms do return, restarting TMS brought back the improvement for most people in the research.

‍

None of that predicts any one person's course. It does show what tends to help results last, and why the months after treatment deserve a plan of their own.

What "Lasting" Means: Response vs. Remission

Two terms do most of the work in durability research. A person has responded when their depression scores fall by at least half on a standard rating scale. They're in remission when scores drop low enough that the depression is largely gone.

‍

Durability studies then ask a narrower question than the original trials did: of the people who responded or reached remission by the end of a course, how many were still doing well months later? That framing matters when you read the numbers. A result such as 62.5% of people keeping their response for a year describes people who had already responded, not everyone who started TMS. Those follow-up checks happen at set points, typically three, six, and 12 months after a course, so durability is reported as the share of people still responding at each checkpoint.

What the Research Shows About Durability

The most direct data come from a 2014 study in The Journal of Clinical Psychiatry that followed people with medication-resistant major depression for a year after they finished TMS at 42 U.S. clinical practices. Of the 257 people who completed a course and agreed to follow-up, 120 had responded or reached remission by the end of treatment. Of those 120, 75 (62.5%) kept meeting response criteria through the full 12 months.

‍

Two details shape that result. The study used a practical approach after the course: continued antidepressant medication, plus access to more TMS if symptoms returned. And over the year, 93 participants (36.2%) had TMS reintroduced at some point, averaging about 16 treatment days. So the 62.5% reflects TMS inside ongoing care, not a single course left to stand on its own.

‍

A 2019 meta-analysis in Brain Stimulation pooled 19 studies of people who had responded to a TMS course. About two-thirds were still responding at three months, about 53% at six months, and about 46% at one year. The authors' summary: roughly half of responders keep their response for up to a year after a successful course.

‍

Read together, the two studies give a realistic range of around half to nearly two-thirds of responders still doing well a year out. The other side of those numbers matters just as much. A meaningful share of people see symptoms return within the first year, and planning for that possibility is part of good care, not a sign that treatment failed.

Factors That Influence How Long Results Last

The research has identified a few patterns, mostly at the level of groups rather than individuals:

‍

  • Maintenance treatment. In the 2019 meta-analysis, studies that included maintenance treatment showed higher sustained response at some time points.
  • The mix of people studied. Studies with a higher proportion of women also showed higher sustained response, a group-level pattern that says nothing reliable about any one person.
  • Continued medication. The best-known durability results come from people who stayed on antidepressants after TMS, so those numbers describe that combination.
  • A completed course. Durability figures come from people who finished a full acute course. They don't describe what happens after a partial one.

‍

Clinicians also weigh a person's history when planning follow-up, such as how many depressive episodes they've had and how many treatments failed before TMS. The findings above don't establish how much those factors change the odds, so they inform a clinician's judgment rather than supply a number.

Maintenance TMS: What It Is and Who May Need It

TMS maintenance treatment means periodic sessions after the main course, scheduled to protect a response rather than to answer a relapse. Schedules vary between providers and between people, and no single schedule has become standard.

‍

The evidence supports the idea without settling the details. The 2019 meta-analysis found maintenance associated with more durable response, and its authors suggested maintenance be considered in practice and tested in future trials. That's a promising signal, not a proven protocol. Maintenance TMS is also separate from staying on medication: in both the year-long and six-month studies, people continued antidepressants whether or not they received more TMS.

‍

Not everyone needs it. Some people stay well for long stretches without it. Whether maintenance makes sense for a particular person is a judgment a psychiatrist makes from their history and how they're doing in the months after the course.

Can TMS Be Repeated If Symptoms Return?

Yes, and the research on restarting TMS is among the most reassuring parts of this topic. In a six-month study in Brain Stimulation, people whose depression had improved by at least a quarter with TMS stopped treatment gradually over three weeks while starting maintenance antidepressant medication. In that study, worsening had a specific meaning: a clinician-rated decline that held for two consecutive weeks, which triggered restarting TMS. Over the next 24 weeks, 38% had symptoms worsen enough to restart TMS, and 32 of those 38 people (84%) regained their improvement. Only 10% of the 99 people whose results were reported met the study's definition of relapse.

‍

A repeat course is different from maintenance. Maintenance is planned in advance to hold a response; a repeat course starts because symptoms have come back. In the year-long study described above, about a third of participants had TMS reintroduced at some point. Whether and when to restart is a decision made with a psychiatrist, based on how symptoms are changing.

What Helps Results Last Longer

Beyond maintenance and continued medication, two more things help, though neither promises that results will last for a particular person:

‍

  • Catching changes early. In the six-month study, regular assessments flagged worsening symptoms, and most people who restarted TMS at that point regained their improvement.
  • Staying connected to care. Therapy and regular psychiatric visits mean someone is watching for early changes between treatments.

‍

Knowing what returning depression tends to look like makes early changes easier to catch: shifts in sleep or appetite, lower energy, less interest in usual activities, and a low mood that lingers instead of lifting after a few days. When those signs show up, reaching out sooner gives a care team more options, and our guide on how to ask for help when depressed covers how to start that conversation.

‍

These describe what research associates with better long-term results in groups of patients. They aren't instructions for any one person's treatment plan; that's a psychiatrist's call, made with the whole history in view.

Talking to a Psychiatrist About a Long-Term Plan

A TMS course is the start of a plan, not the end of one. The months afterward are when follow-up, medication decisions, and a clear plan for what happens if symptoms return matter most.

‍

At Amae, TMS sits inside our integrated care model, where psychiatric care, therapy, primary care, and peer support stay linked after the course ends. We provide TMS therapy for major depressive disorder at our Los Angeles clinic and at our Bay Area clinics in Los Altos and San Mateo. Commercial insurance plans and cash pay are both accepted, and our intake team handles prior authorization. To map out what comes after a course, talk with an Amae psychiatrist about a long-term plan. Anyone in crisis can reach the 988 Suicide and Crisis Lifeline by call or text.

Frequently Asked Questions

How long do TMS results typically last?

For many people, months to a year or longer, though it varies. In a year-long study of people who responded to TMS, 62.5% kept meeting response criteria for the full 12 months. A 2019 meta-analysis found that about half of responders were still responding at one year.

What percentage of people relapse after TMS?

Some return of symptoms within a year is common. In the 2019 meta-analysis, roughly half of responders were no longer responding at one year. That isn't always a full relapse: in a six-month study, 38% had symptoms worsen enough to restart TMS, while 10% met the study's definition of relapse.

Can TMS be repeated if depression comes back?

Yes. In a six-month study, 84% of people whose symptoms worsened regained their improvement when TMS was restarted. A repeat course is different from ongoing maintenance sessions, and the decision is made with a psychiatrist based on individual history.

Do I need maintenance TMS sessions after my initial course?

Not necessarily. Some people stay well without them, and there is no standard maintenance schedule across providers. Research links maintenance with longer-lasting response, so whether it fits is a decision a psychiatrist makes based on your response and how closely symptoms are being monitored.

What can help TMS results last longer?

The research points to planned follow-up, continued medication when it's part of the plan, and catching symptom changes early. These are general findings from groups of patients, not instructions for any one person's treatment.

Is maintenance TMS covered by insurance?

It depends on the insurer and on whether sessions are billed as maintenance or as a new course for returning symptoms, since coverage can differ between the two. Ask the provider to verify benefits with your insurer before sessions begin.

‍

Citations

  1. Dunner DL, Aaronson ST, Sackeim HA, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. Journal of Clinical Psychiatry. 2014;75(12):1394-1401. https://pubmed.ncbi.nlm.nih.gov/25271871/
  2. Senova S, Cotovio G, Pascual-Leone A, Oliveira-Maia AJ. Durability of antidepressant response to repetitive transcranial magnetic stimulation: systematic review and meta-analysis. Brain Stimulation. 2019;12(1):119-128. https://pubmed.ncbi.nlm.nih.gov/30344109/
  3. Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation. 2010;3(4):187-199. https://pubmed.ncbi.nlm.nih.gov/20965447/
  4. 988 Suicide and Crisis Lifeline. https://988lifeline.org

‍

# min read

Spravato vs Ketamine Infusions: Key Differences

By

Sonia Garcia

|

October 16, 2026

Comparing Spravato vs ketamine infusion treatment means comparing two versions of the same idea: using ketamine's fast action on the brain's glutamate system to treat depression that standard antidepressants haven't relieved. The best comparison so far, a 2025 meta-analysis by Mayo Clinic researchers, found no statistically significant difference in how often the two lead to response or remission. What separates them is everything around the drug: FDA status, how it's given, how quickly it tends to work, what it costs, and who pays.

‍

So far, neither has been shown to be the better drug.

What Is Spravato (Esketamine)?

Esketamine vs ketamine comes down to chemistry. Standard ketamine is an equal mix of two mirror-image forms of the same molecule. Esketamine is one of those forms on its own, and Spravato is esketamine delivered as a nasal spray.

‍

The FDA first approved Spravato in 2019 for treatment-resistant depression, taken together with an oral antidepressant, as the Mayo Clinic review notes. A second approval, again paired with an oral antidepressant, covers depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior. And the most recent change came in January 2025, when the FDA added standalone use for treatment-resistant depression, as the current prescribing information shows.

‍

Every dose happens in a certified healthcare setting under the Spravato REMS, an FDA-required safety program. Each device delivers 28 mg, and a session uses two or three devices (56 or 84 mg), with a five-minute wait after each one. You're then monitored for at least two hours, and you can't drive again until the next day, once you've had a restful night's sleep. The label sets the early schedule: twice a week for weeks one through four, once a week for weeks five through eight, then weekly or every two weeks, adjusted to the least frequent dosing that maintains the response.

What Is Ketamine Infusion Therapy?

A ketamine infusion uses standard ketamine, both mirror-image forms together, delivered through an IV line. Ketamine has been FDA-approved as an anesthetic since 1970, but for depression, IV ketamine "remains an off-label treatment," in the Mayo Clinic review's words. Off-label prescribing is legal and common in medicine. It also means there is no FDA-approved depression regimen, so dosing schedules and safety protocols are set by each clinic.

‍

The most studied dose is 0.5 mg per kilogram of body weight, infused over about 40 minutes with continuous heart and blood pressure monitoring. A first course typically runs two to three infusions a week for about three to six treatments, followed by maintenance sessions on a schedule that varies from clinic to clinic.

Spravato vs Ketamine Infusion: Side-by-Side Comparison

Feature Spravato (esketamine) IV ketamine infusion
What it contains Esketamine, one mirror-image form of ketamine Ketamine, both mirror-image forms
FDA status for depression Approved for treatment-resistant depression (2019 with an oral antidepressant; monotherapy added January 2025) and for major depressive disorder with acute suicidal thoughts Off-label; FDA-approved as an anesthetic
How it's given Nasal spray you use yourself, under supervision IV line placed by clinic staff
Typical dose 56 or 84 mg per session About 0.5 mg per kg of body weight
Time in the clinic Two or three devices, five minutes apart, then at least two hours of monitoring About 40 minutes of infusion, plus recovery time
Safety rules Federal REMS program; certified settings only Set by each clinic
Adjusting mid-session A dose can't be reduced once it's sprayed The infusion can be slowed or stopped
Early schedule Twice weekly for four weeks, then weekly Two to three times weekly, about three to six treatments
Insurance More consistently covered when criteria are met Often self-pay

Efficacy: What the Research Shows

The most complete head-to-head evidence is the 2025 Mayo Clinic meta-analysis in Therapeutic Advances in Psychopharmacology. The authors identified eight studies with 978 patients in total. Only one was a randomized trial, and it compared IV ketamine with an IV form of esketamine rather than the nasal spray, so the pooled comparison rests on observational studies of IV ketamine versus nasal esketamine.

‍

In those studies, the odds of response were 1.26 times higher with IV ketamine and the odds of remission 1.31 times higher, but neither difference was statistically significant. The authors concluded that the evidence suggests no significant difference in short-term efficacy, with a slight numerical trend favoring IV ketamine.

‍

Speed may be where the two differ. In one Mayo Clinic observational study included in the review, people reached remission after a median of two IV ketamine treatments, compared with seven nasal esketamine treatments. That's a real gap in lived experience. But it comes from observational data, where the people who choose or can access each treatment may differ in ways a study can't fully account for.

‍

So is Spravato better than ketamine infusions? On current evidence, neither has been shown to be. A randomized trial built to settle the question, called EQUIVALENCE, plans to assign 400 people to one treatment or the other for eight sessions over four weeks. Its protocol was published in 2026, and results are not yet available.

FDA Approval and Insurance Coverage

FDA approval changes who pays. Because Spravato has approved indications, insurers can write coverage criteria around it, and they typically require prior authorization and documentation of earlier antidepressant trials. Ketamine infusions for depression are off-label, so coverage is inconsistent, and many people pay out of pocket.

‍

The Spravato vs ketamine cost comparison has a twist. Economic modeling cited in the Mayo Clinic review found nasal esketamine unlikely to be cost-effective compared with IV ketamine from a health-system perspective. Yet an individual patient's out-of-pocket cost for Spravato may be lower, thanks to insurance coverage or manufacturer assistance. Published price estimates vary too widely by dose, frequency, and coverage to quote a single figure, so ask each provider and your insurer for the numbers that apply to you.

Side Effects and Safety Considerations

Because both drugs act on the same receptor, their side effects overlap. In Spravato's clinical trials, 48% to 61% of people developed sedation, and 61% to 84% experienced dissociative or perceptual changes, such as distortions of time or space, according to the prescribing information. Dizziness, nausea, vertigo, anxiety, and a temporary rise in blood pressure are also common, which is why blood pressure is rechecked about 40 minutes after dosing. IV ketamine produces the same family of effects, concentrated during and shortly after the infusion.

‍

Direct safety comparisons are limited. In one retrospective analysis included in the Mayo Clinic review, a rise in blood pressure during treatment occurred in 45% of IV ketamine patients versus 9.2% of nasal esketamine patients, and dissociative effects were also more frequent with IV ketamine, though they were described as transient. That is one retrospective study. It doesn't establish either drug as safer overall.

‍

Both drugs carry a potential for misuse, which shapes who is a candidate, and each has its own exclusions. Spravato, for example, isn't used in people with aneurysmal blood vessel disease, an arteriovenous malformation, or a history of bleeding in the brain.

What Influences the Choice Between Them

There isn't a universal right answer. A psychiatrist weighing the two usually considers:

‍

  • Coverage and cost. Whether insurance will cover Spravato in your situation, and whether infusions are affordable out of pocket.
  • How quickly relief is needed. Early data suggest infusions may reach remission in fewer sessions, which matters more when symptoms are severe.
  • Medical history. Blood pressure, vascular conditions, and any history of substance misuse.
  • Route. Some people would rather avoid an IV line. Others prefer an infusion that can be slowed or stopped.
  • Logistics. Spravato means at least two hours in the clinic and no driving until the next day, twice a week at first. Infusions take about 40 minutes, plus recovery time that varies by clinic.
  • Continuity. Whether you're already established with a psychiatrist or clinic that offers one of them.

‍

The choice belongs in a conversation with a psychiatrist who knows your treatment history, not in a ranking of favorites.

Making the Decision With a Psychiatrist

Spravato and ketamine infusions are tools for treatment-resistant depression, not a complete plan. They work alongside medication, therapy, and ongoing psychiatric care, and they sit among other options, including TMS therapy for depression that hasn't responded to medication. When depression brings thoughts of suicide, care for suicidal thoughts comes first.

‍

We don't offer Spravato at Amae. Our psychiatrists treat depression that hasn't responded to medication through our integrated care model, with therapy, medication management, and TMS, which we provide in Los Altos, San Mateo, and Los Angeles. Whether the question is Spravato vs ketamine infusion or something else entirely, talk through your options with an Amae psychiatrist, including ones we don't provide ourselves. For anyone in crisis right now, 988 is a call or text away.

Frequently Asked Questions

Is Spravato more effective than ketamine infusions?

Not on current evidence. A 2025 meta-analysis found no statistically significant difference in response or remission between IV ketamine and nasal esketamine, only a slight numerical trend favoring IV ketamine. Most of that evidence is observational, and a large randomized head-to-head trial is still underway.

Which works faster, Spravato or ketamine infusions?

IV ketamine may reach remission in fewer sessions. In one observational study, the median was two IV infusions versus seven nasal esketamine treatments. Because that finding comes from observational data rather than a randomized trial, treat it as preliminary.

Is Spravato safer than ketamine infusions?

Neither has been established as safer overall. The two share a similar side-effect profile because they act on the same receptor. One retrospective comparison found more blood pressure spikes and dissociation with IV ketamine, but a single study can't settle the question, and individual risk depends on your medical history.

Why is Spravato covered by insurance but ketamine infusions often aren't?

Spravato has FDA approval for treatment-resistant depression, which gives insurers defined criteria for covering it, usually with prior authorization. IV ketamine for depression is off-label, so coverage is inconsistent and infusions are often self-pay.

Can I switch between Spravato and ketamine infusions?

That's a clinical decision to make with a psychiatrist, based on how you've responded, the side effects you've had, your goals, and your coverage. It isn't something to change on your own.

How many sessions does each treatment typically require?

Spravato starts at twice a week for four weeks, then weekly, then weekly or every two weeks based on response. Ketamine infusions often begin with three to six sessions given two to three times a week, followed by maintenance on a schedule that varies by clinic.

‍

Citations

  1. Elmosalamy A, Tarikogullari I, Patarroyo-Rodriguez L, et al. Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12615959/
  2. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information, revised January 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
  3. Wilkinson ST, Prashad S, Dalthorp R, et al. Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: the EQUIVALENCE trial protocol. Contemporary Clinical Trials. 2026;164:108273. https://pubmed.ncbi.nlm.nih.gov/41780747/
  4. 988 Suicide and Crisis Lifeline. https://988lifeline.org

‍

# min read

Dual Diagnosis vs Co-Occurring Disorders: Understanding the Differences

By

Sonia Garcia

|

November 10, 2026

Maybe a doctor wrote "dual diagnosis" in a discharge summary, and a treatment program's website says "co-occurring disorders." You're left wondering whether your family member has one condition, two, or something different from what you thought. Here's the short answer to the dual diagnosis vs co-occurring disorders question: they describe the same situation. Both terms mean a person has a mental health condition and a substance use disorder at the same time. The difference is in the wording, not the illness.

Dual diagnosis vs co-occurring disorders: what each term means

Co-occurring disorders is the term SAMHSA, NIDA, and NIMH use today. The Substance Abuse and Mental Health Services Administration (SAMHSA) uses it to describe a person who has at least one mental disorder and at least one substance use disorder, with each diagnosable on its own rather than one simply being a symptom of the other.

Dual diagnosis is another name for the same thing. SAMHSA's treatment guidance uses "co-occurring disorders" as its main term, and you'll see both on websites and in paperwork.

So if two websites seem to disagree, they're probably using different words for one clinical picture. What matters for care is which specific conditions are present and how severe each one is.

How common co-occurring disorders are

More common than most families expect. The National Institute on Drug Abuse notes that people with substance use disorders often have co-occurring mental disorders, and the reverse is true too. As NIDA notes, people treated for one condition can be screened for the other.

Two conditions, one person. Not two separate problems.

Why the two conditions feed each other

The relationship runs in both directions, and the National Institute of Mental Health points to several ways they connect:

  1. Shared risk factors. Genetics, chronic stress, and trauma raise the risk of both mental disorders and substance use disorders.
  2. Using substances to cope. Someone with untreated anxiety may drink to get through the evening. It works briefly, then makes the underlying condition worse.
  3. Substance use changing the brain. Repeated use can alter brain systems in ways that raise the risk of developing other mental disorders.

Which came first? Often, nobody can say for sure, and treatment doesn't wait for the answer.

Why diagnosis is harder when both are present

Intoxication and withdrawal can look almost exactly like psychiatric symptoms. Alcohol withdrawal, for example, can produce anxiety that's hard to tell apart from an anxiety disorder.

This is why a careful evaluation looks at timing: did the symptoms exist before the substance use, or do they persist for about a month or more after it stops? SAMHSA's TIP 42, following DSM-5, uses this test to separate an independent mental disorder from a substance-induced one. A firm answer can take weeks or months of abstinence.

It's worth the wait, because the answer informs the treatment plan. Picture someone whose untreated bipolar disorder drives their drinking: treat only the alcohol use and relapse is likely. Or someone whose anxiety was withdrawal all along: they may not need long-term psychiatric medication at all.

What integrated treatment looks like

For years, people with co-occurring disorders were told to get sober first, then address their mental health, or the reverse. Two separate systems, two separate teams, and the person caught in between.

The current standard is integrated treatment, which NIMH describes as care that combines mental health and substance use treatment rather than splitting it across providers. In practice, that usually means:

  • One coordinated treatment plan that names every condition and how each one affects the others
  • Psychiatric care that accounts for substance use when choosing and monitoring medications
  • Therapy for both conditions together, using approaches such as cognitive behavioral therapy and motivational interviewing
  • The right level of care, which may mean a structured outpatient program several days a week rather than a single weekly appointment
  • Support for physical health, sleep, and daily routines, since both conditions take a toll on the body

Medication choices are individual and depend on the specific diagnoses, the substances involved, and the person's history. That decision belongs with a psychiatrist who knows the full picture.

How we treat co-occurring disorders at Amae Health

Co-occurring substance use disorder is one of the conditions our clinics specialize in, alongside the severe mental illness (SMI) diagnoses we treat every day: schizophrenia, bipolar disorder, major depressive disorder, and borderline personality disorder.

Our care model brings a multidisciplinary team under one roof. Psychiatrists manage medication and the overall treatment plan. Therapists provide individual and group therapy. Primary care physicians, dietitians, health coaches, peer mentors, and care coordinators work from the same plan, so nobody has to carry information between offices.

For people who need more structure than weekly visits, we offer a Partial Hospitalization Program (PHP) and an Intensive Outpatient Program (IOP). If you're unsure which fits, our guide to PHP vs. IOP explains the difference.

Frequently asked questions

Is dual diagnosis the same as co-occurring disorders?

Yes. Both terms describe a person who has a mental health condition and a substance use disorder at the same time. "Dual diagnosis" is another name for co-occurring disorders.

Which comes first, the mental illness or the substance use?

It varies. Sometimes a mental health condition comes first and substance use begins as a way to cope. Sometimes substance use comes first and contributes to a mental disorder. Shared risk factors like genetics and trauma can drive both. A good evaluation looks at timing, but treatment can start before the order is clear.

Can both conditions be treated at the same time?

Yes, and federal guidance recommends it. Integrated treatment addresses the mental health condition and the substance use disorder through one coordinated plan instead of sending a person to separate programs in sequence.

What are common examples of co-occurring disorders?

Depression, anxiety, and bipolar disorder are among the mental health conditions NIMH names as often occurring alongside a substance use disorder. Many people also have anxiety and depression together alongside a substance use disorder.

The takeaway

When it comes to dual diagnosis vs co-occurring disorders, the labels differ but the clinical reality is the same: two or more conditions that shape each other and need to be treated together. The term on the paperwork matters far less than whether the care plan addresses all of them at once.

If you or someone you love is living with a mental health condition and substance use, request an intake appointment and a member of our team will talk through what's happening and which level of care fits.

If you're in crisis, call or text 988 to reach the 988 Suicide & Crisis Lifeline.